CJC-1295 No Dac + Ipamorelin Blend [Peptide]

Description

What is the CJC-1295 No DAC + Ipamorelin Blend?

The CJC-1295 No DAC + Ipamorelin Blend is a dual-peptide research preparation combining Modified GRF (1-29) – commonly designated CJC-1295 without DAC – and Ipamorelin, co-formulated to enable simultaneous investigation of two mechanistically complementary GH-releasing pathways in the same experimental system. The combination represents the most widely investigated GHRH analogue + GHS-R1a agonist pairing in GH secretagogue research, based on the hypothesis that GHRHR (cAMP/PKA) and GHS-R1a (IP3/calcium) pathways produce additive or synergistic GH release through non-competing intracellular signalling cascades.

CJC-1295 without DAC (also known as Modified GRF 1-29, Mod GRF 1-29, or tetrasubstituted GRF(1-29)) is a synthetic 29-amino acid analogue of human growth hormone-releasing hormone (hGHRH 1-29) incorporating four amino acid substitutions relative to native GHRH: D-Ala at position 2, Gln→Ala at position 8, Ala→Ala at position 15, and Leu→Leu at position 27 – modifications that collectively increase resistance to dipeptidyl peptidase-4 (DPP-4) and other plasma proteases, extending the half-life to approximately 30 minutes compared to under 7 minutes for endogenous GHRH. Unlike CJC-1295 with DAC, the No DAC form lacks the maleimidopropionic acid moiety at the C-terminal lysine that enables albumin binding – making it a short-acting GHRH analogue that produces discrete pulsatile GH release rather than the sustained plateau produced by the DAC form.

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide GH secretagogue originally developed by Novo Nordisk, characterised as the first selective GHS-R1a agonist – producing GH release without the significant cortisol, prolactin, or appetite-stimulating effects associated with GHRP-6 and other earlier GHRPs. Its sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporates the non-coded 2-aminoisobutyric acid (Aib) at position 1 for DPP-4 resistance and D-2-naphthylalanine (D-2-Nal) at position 3 for enhanced GHS-R1a affinity and selectivity. The selectivity for GH without cortisol/prolactin elevation makes Ipamorelin the preferred GHRP for research protocols where GH axis effects need to be isolated from confounding corticotroph or lactotroph pathway activation.

Neither CJC-1295 without DAC nor Ipamorelin is approved by the Food and Drug Administration for human or veterinary use. Neither CJC-1295 without DAC nor Ipamorelin is a dietary supplement, and neither is intended for human consumption or self-administration. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

How Does the CJC-1295 No DAC + Ipamorelin Blend Work?

The blend’s research rationale is based on dual-pathway GH axis engagement – simultaneously activating the GHRHR (through CJC-1295 No DAC) and GHS-R1a (through Ipamorelin) – using complementary intracellular signalling cascades that together produce additive or synergistic GH release in preclinical preparations.

CJC-1295 No DAC – GHRHR Activation and cAMP/PKA Pathway

CJC-1295 without DAC binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells with the same receptor pharmacology as full-length GHRH and Sermorelin (GRF 1-29). GHRHR is a Gαs-coupled GPCR; receptor activation initiates adenylyl cyclase stimulation, generating elevated intracellular cAMP and downstream protein kinase A (PKA) activation [Jetté et al., 2005]. This cascade promotes GH1 gene transcription and triggers exocytosis of stored GH secretory granules. The four amino acid substitutions (D-Ala2, Ala8, Ala15, Leu27) improve DPP-4 resistance and extend activity duration to approximately 30 minutes – producing discrete, physiologically-timed GH pulses when administered before expected natural GH pulses in preclinical research protocols.

Ipamorelin – GHS-R1a Activation and Calcium Pathway

Ipamorelin binds GHS-R1a (ghrelin receptor) with high selectivity, activating Gαq-coupled intracellular signalling through phospholipase C, IP3-mediated calcium mobilisation from intracellular stores, and potassium channel inhibition [Raun et al., 1998]. These calcium-dependent signals directly stimulate GH granule exocytosis through a mechanism complementary to but distinct from the GHRHR cAMP/PKA pathway. Critically, Ipamorelin achieves this GH release without the significant cortisol, prolactin, FSH, LH, or TSH changes observed with GHRP-6 in matched porcine and rodent preparations – confirming GHS-R1a selectivity [Raun et al., 1998]. This hormonal specificity makes Ipamorelin the preferred GHS-R1a agonist for research protocols where GH pathway isolation is required.

Synergistic Dual-Pathway GH Release

The GHRHR/cAMP/PKA cascade (CJC-1295 No DAC) and GHS-R1a/Gαq/calcium cascade (Ipamorelin) converge on GH exocytosis through parallel, non-competing intracellular mechanisms. In preclinical preparations, combined GHRH analogue + GHS-R1a agonist administration consistently produces greater GH pulse amplitudes than either compound alone – attributed to the summation of two independent GH release triggers acting simultaneously on the same somatotroph cell population. Additionally, GHS-R1a agonism (like GHRP-6) suppresses hypothalamic somatostatin release, reducing the primary GH inhibitory signal and further amplifying GHRHR-mediated GH release. This dual mechanism provides both direct GH release and indirect disinhibition, producing the characteristic supraphysiological GH response seen with GHRH + GHS combinations.

Ipamorelin Selectivity Advantage for Blend Research

Unlike GHRP-6 in a GHRH+GHRP combination, Ipamorelin’s GHS-R1a selectivity means the blend produces GH axis stimulation with minimal confounding corticotroph (ACTH/cortisol) or lactotroph (prolactin) pathway activation. In preclinical porcine studies, Ipamorelin at 420 nmol/kg did not significantly alter FSH, LH, prolactin, or TSH concentrations despite robust GH release [Raun et al., 1998]. This selectivity profile makes the CJC-1295 No DAC + Ipamorelin combination the research standard for studying GH axis activation in isolation, without the neuroendocrine confounders associated with GHRP-6 or hexarelin.

Key Research Findings

In preclinical and clinical research contexts, the individual blend components have been associated with the following observations. No peer-reviewed published study has directly characterised the CJC-1295 No DAC + Ipamorelin blend as a combined preparation in a head-to-head controlled experimental comparison against individual components.

• Ipamorelin GH selectivity: Ipamorelin produced robust GH release in porcine in vivo models without significant FSH, LH, prolactin, or TSH changes at 420 nmol/kg; the first characterised selective GHS-R1a agonist [Raun et al., 1998].
• Ipamorelin GHS-R1a binding: Ki 63.4 nM in COS-7 cells expressing GHS-R1a; EC50 1.3 nM in primary rat pituitary cells for GH release; IP3 accumulation in BHK cells expressing GHS-R1a (EC50 46.9 nM).
• Modified GRF 1-29 GHRHR activity: Tetrasubstituted GRF(1-29) demonstrated GHRHR receptor activation and GH release in anterior pituitary rat preparations; identified as the core GHRH analogue sequence in the CJC-1295 programme [Jetté et al., 2005].
• Ipamorelin human PK/PD: Phase 1 pharmacokinetic-pharmacodynamic modelling in human volunteers demonstrated dose-dependent GH release following Ipamorelin with a half-life of approximately 2 hours [Gobburu et al., 1999].
• GHRH + GHS synergy (class-level): Combined GHRH + GHS-R1a agonist administration consistently produces supraphysiological GH pulse amplitudes exceeding either compound alone in preclinical and human model preparations; mechanism attributed to complementary cAMP/PKA + calcium signalling cascades plus somatostatin suppression.

All findings listed above are derived from preclinical in vitro and in vivo data and early-phase human pharmacology studies. No peer-reviewed data specifically characterises the CJC-1295 No DAC + Ipamorelin blend as a combined preparation. These observations do not constitute evidence of efficacy or safety for research-grade material in any human condition or organism.

What are the Potential Research Applications?

In controlled laboratory environments, the blend has been investigated for the following research applications. These do not constitute claims of efficacy or safety in any organism.

Dual-Pathway GH Axis Stimulation Research. The blend is employed in studies characterising the additive or synergistic relationship between GHRHR (cAMP/PKA) and GHS-R1a (Gαq/calcium) GH release pathways in isolated pituitary somatotroph preparations and rodent in vivo models. Research examines intracellular signal convergence mechanisms, GH pulse amplitude profiles, and the relative contributions of each receptor pathway to total GH release.

Pulsatile GH Secretion and Somatotroph Biology Research CJC-1295 No DAC’s short half-life (~30 min) enables discrete GH pulse induction in rodent in vivo models, mimicking physiological GH pulsatility. Combined with Ipamorelin’s GHS-R1a/somatostatin suppression contribution, the blend produces physiologically relevant GH pulse profiles for studying somatotroph secretory dynamics, GH gene expression, and pituitary hormone release kinetics.

Selective GH Axis Research Without Confounders Ipamorelin’s hormonal selectivity profile enables GH axis research with minimal cortisol, prolactin, or gonadotrophin pathway interference – critical for isolating GH-specific downstream effects in metabolic, anabolic, and body composition pathway studies in preclinical rodent preparations.

IGF-1 Axis and Downstream Pathway Studies. In rodent in vivo models, the blend is employed to characterise downstream GH axis activation, including hepatic IGF-1 production, IGF-1 receptor signalling, and growth marker responses. Research examines how combined GHRHR + GHS-R1a engagement alters IGF-1 pulse profiles relative to individual compound administration.

Comparative GH Secretagogue Pharmacology The CJC-1295 No DAC + Ipamorelin blend serves as the selective reference preparation in comparative studies against GHRP-6-containing protocols, CJC-1295 with DAC (sustained vs. pulsatile), and other GHRH + GHRP combinations – characterising how secretagogue selectivity and pharmacokinetic profile alter GH axis research outcomes.

What are the Potential Side Effects?

The following observations are from preclinical and early clinical pharmacology data for the individual components.

• GH axis activation consistent with somatotroph stimulation – water retention, transient insulin sensitivity changes – observed at higher doses in clinical pharmacology studies; consistent with GH class effects
• Ipamorelin: no significant cortisol, prolactin, FSH, LH, or TSH changes reported in preclinical porcine studies at GH-releasing doses – key selective profile confirmed [Raun et al., 1998]
• CJC-1295 No DAC: no significant adverse effects reported at research-relevant doses in preclinical preparations; injection site reactions at low frequency in subcutaneous administration models
• No human safety or tolerability data have been established for research-grade CJC-1295, No DAC or Ipamorelin outside pharmacological study protocols. These observations should not be extrapolated to research-grade material.

Risk & Handling

Handling Precautions

CJC-1295 No DAC + Ipamorelin Blend should only be handled by trained laboratory personnel. Appropriate PPE is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with lyophilized powder, use within a laminar flow cabinet. Avoid aerosol generation during reconstitution. Apply precautions appropriate to both active peptide components simultaneously.

Exposure Risks

Risk Tier: MODERATE

Both blend components are pharmacologically active at their respective pituitary receptor targets. Accidental systemic exposure at research concentrations may produce GH axis stimulation through complementary GHRHR and GHS-R1a pathways. Ipamorelin’s selectivity means cortisol and prolactin confounders are minimal compared to GHRP-6-containing preparations, but GH axis effects from accidental exposure would be expected. No human safety data has been established for research-grade preparations of either component.

Storage

• Lyophilized blend: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles; the integrity of both peptide components may be compromised
• Protect from light; Ipamorelin contains a 2-naphthylalanine residue sensitive to photodegradation

Frequently Asked Questions

Q: What is the CJC-1295 No DAC + Ipamorelin blend, and why are the two compounds combined? A: The blend combines Modified GRF 1-29 (CJC-1295 without DAC; a short-acting GHRH analogue) and Ipamorelin (a selective GHS-R1a agonist) to simultaneously investigate two complementary GH-releasing pathways. CJC-1295 No DAC activates GHRHR (cAMP/PKA pathway); Ipamorelin activates GHS-R1a (Gαq/calcium pathway). The non-overlapping signalling cascades produce additive or synergistic GH release in preclinical preparations. Neither compound is FDA-approved; both are intended strictly for laboratory research purposes.

Q: What is the key difference between CJC-1295 with DAC and CJC-1295 without DAC? A: CJC-1295 with DAC carries a maleimidopropionic acid moiety (Drug Affinity Complex, DAC) that covalently binds albumin in vivo, extending half-life to 5.8–8.1 days for sustained GH elevation. CJC-1295 without DAC (Modified GRF 1-29) lacks this moiety entirely, producing a short half-life of approximately 30 minutes and discrete, physiologically-timed GH pulses. The No DAC form is used when pulsatile GH release protocols are required; the DAC form is used when sustained GH elevation is the research objective. Wikipedia explicitly notes that these two compounds are incorrectly equated in several scientific papers.

Q: What makes Ipamorelin a preferred GHS-R1a agonist versus GHRP-6? A: Ipamorelin is characterised as the first selective GHS-R1a agonist – producing robust GH release without the significant cortisol, prolactin, FSH, LH, or TSH elevations observed with GHRP-6 in preclinical porcine preparations [Raun et al., 1998]. In research protocols where GH axis effects need to be isolated from neuroendocrine confounders, Ipamorelin’s selectivity profile makes it the preferred GHS-R1a agonist. GHRP-6’s broader hormonal footprint, while useful in appetite circuit research, introduces confounders in pure GH axis pharmacology studies.

Q: Why does the GHRH + GHS combination produce more GH than either compound alone? A: GHRHR (activated by CJC-1295 No DAC) signals through Gαs/cAMP/PKA; GHS-R1a (activated by Ipamorelin) signals through Gαq/IP3/calcium. These are entirely separate intracellular cascades that converge on GH exocytosis at the same somatotroph cell. Additionally, GHS-R1a agonism suppresses hypothalamic somatostatin release, reducing the principal GH inhibitory signal – an indirect amplification mechanism unavailable to GHRH alone. The combined effect of two independent direct stimulatory cascades plus somatostatin disinhibition produces the characteristic supraphysiological GH response seen with GHRH + GHS combinations.

Q: Is there dedicated peer-reviewed research on this specific blend? A: No peer-reviewed study has directly characterised the CJC-1295 No DAC + Ipamorelin combined preparation in a controlled head-to-head comparison against individual components in matched preclinical models. The research rationale for the combination is inferred from the well-characterised individual mechanisms of each component and the established principle of GHRH + GHS-R1a agonist synergy in GH release from preclinical and clinical pharmacology literature.

Q: What is the WADA status of the blend? A: Both components are explicitly prohibited at all times under S2.2.4 (Growth Hormone Releasing Factors) of the 2026 WADA Prohibited List – CJC-1295 No DAC as a GHRH analogue and Ipamorelin as a growth hormone secretagogue. Verify at GlobalDRO.com. Researchers in sport-adjacent contexts must verify the current status at GlobalDRO.com before use.

Related Research Compounds

Researchers investigating the CJC-1295 No DAC + Ipamorelin Blend may also be interested in the following compounds currently available for laboratory research at RCDbio:

• GHRP-6 – The founding GHS-R1a agonist; provides the broad-spectrum GHS-R1a reference compound for comparative studies examining Ipamorelin’s selective profile versus GHRP-6’s broader hormonal footprint in matched GH secretagogue protocols.
• Tesamorelin Nasal Spray – An FDA-approved GHRH analogue (Egrifta); provides the clinically validated GHRH axis pharmacology reference point for comparative GH secretagogue research.

All products listed are for laboratory and research purposes only.

References

1. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin is the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ 
2. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone-releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://pubmed.ncbi.nlm.nih.gov/10497635/ 
3. Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology, 146(7), 3052–3058. https://pubmed.ncbi.nlm.nih.gov/15817669/ 
4. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/ 

Disclaimer

CJC-1295 No DAC + Ipamorelin Blend is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not approved CJC-1295 No DAC or Ipamorelin for any indication. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@legacy.rcdbio.co